How have ZTS shares performed this year?

Zoetis' stock was trading at $197.37 at the start of the year. Since then, ZTS shares have decreased by 7.4% and is now trading at $182.81. View the best growth stocks for 2024 here .

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) announced its quarterly earnings data on Tuesday, August, 6th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis's revenue for the quarter was up 8.3% on a year-over-year basis. Read the conference call transcript .

What is Kristin Peck's approval rating as Zoetis' CEO?

50 employees have rated Zoetis Chief Executive Officer Kristin Peck on Glassdoor.com . Kristin Peck has an approval rating of 82% among the company's employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

Does Zoetis have any subsidiaries?

Zoetis subsidiaries include Jorox Pty, Virtual Recall, Fish Vet Group, Performance Livestock Analytics, Ethos Diagnostic Science, ZNLabs, Phoenix Lab, and more.

Who are Zoetis' major shareholders?

Zoetis' top institutional shareholders include Bank of New York Mellon Corp (1.03%), Unisphere Establishment (0.98%), Legal & General Group Plc (0.92%) and Banque Pictet & Cie SA (0.54%). Insiders that own company stock include Kristin C Peck , Heidi C Chen , Roxanne Lagano , Willie M Reed , Robert J Polzer , Glenn David , Roman Trawicki and Gregory Norden . View institutional ownership trends .

How do I buy shares of Zoetis?

Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zoetis investors own include Xtrackers California Municipal Bond ETF (CA) , Endologix (ELGX) , BlackRock (BLK) , Chipotle Mexican Grill (CMG) , Hawkins (HWKN) , Aegean Marine Petroleum Network (ANW) and Athabasca Oil (ATH) .

NYSE:ZTS

Zoetis (ZTS) Stock Price, News & Analysis

$182.81

-0.79 (-0.43%)

(As of 08/21/2024 ET)

Compare

Today's Range: $181.82
▼
$184.53
50-Day Range: $167.92
▼
$188.38
52-Week Range: $144.80
▼
$201.92

Volume: 1.25 million shs
Average Volume: 2.73 million shs
Market Capitalization: $83.42 billion

P/E Ratio: 35.22
Dividend Yield: 0.94%
Price Target: $217.11

Get Zoetis alerts:

Zoetis MarketRank™ Stock Analysis

Analyst Rating: Buy
3.11 Rating Score
Upside/Downside: 18.8% Upside
$217.11 Price Target
Short Interest: Healthy
1.03% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -4.66
Upright™ Environmental Score
News Sentiment: 0.63
Based on 14 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 9.59%
From $5.84 to $6.40 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.60 out of 5 stars

Medical Sector

75th out of 924 stocks

Pharmaceutical Preparations Industry

25th out of 426 stocks

2.6

Analyst's Opinion

Consensus Rating
Zoetis has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Zoetis has only been the subject of 4 research reports in the past 90 days.
Read more about Zoetis' stock forecast and price target.

5.0

Short Interest

Percentage of Shares Shorted
1.03% of the float of Zoetis has been sold short.
Short Interest Ratio / Days to Cover
Zoetis has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Zoetis has recently decreased by 12.26%, indicating that investor sentiment is improving significantly.

3.3

Dividend Strength

Dividend Yield
Zoetis has a dividend yield of 0.94%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Zoetis has been increasing its dividend for 13 years.
Dividend Coverage
The dividend payout ratio of Zoetis is 33.14%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Zoetis will have a dividend payout ratio of 26.88% next year. This indicates that Zoetis will be able to sustain or increase its dividend.
Read more about Zoetis' dividend.

0.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Zoetis has received a -79.93% net impact score from Upright. The largest negative impact of Zoetis in category "GHG emissions" seems to be driven mostly by its "Cattle antibiotics", "Cattle vaccines", "Vaccines for pet animals", "Antibiotics for pet animals", and "Cattle dewormers" products. See details.
Environmental Sustainability
The Environmental Impact score for Zoetis is -4.66.

3.7

News and Social Media Coverage

News Sentiment
Zoetis has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 14 news articles for Zoetis this week, compared to 11 articles on an average week.
Search Interest
26 people have searched for ZTS on MarketBeat in the last 30 days. This is an increase of 44% compared to the previous 30 days.
MarketBeat Follows
17 people have added Zoetis to their MarketBeat watchlist in the last 30 days. This is an increase of 13% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zoetis insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.16% of the stock of Zoetis is held by insiders.
Percentage Held by Institutions
92.80% of the stock of Zoetis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Read more about Zoetis' insider trading history.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Zoetis are expected to grow by 9.59% in the coming year, from $5.84 to $6.40 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zoetis is 35.22, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.68.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zoetis is 35.22, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 131.77.
Price to Earnings Growth Ratio
Zoetis has a PEG Ratio of 2.81. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Zoetis has a P/B Ratio of 16.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
Read more about Zoetis' valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Air Force quietly working with sub $10 stock on new tech

There is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.

You need to check out the full story right here.

About Zoetis Stock (NYSE:ZTS)

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

ZTS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ZTS Stock News Headlines

August 13, 2024 | marketbeat.com

Which Pet Stock Should Get Your Tail Wagging in 2024? (ZTS)

ZTS stock and CHWY stock have different investment cases, but here's what investors may want to consider before buying either of these pet stocks

August 20 at 4:24 PM | finance.yahoo.com

Zoetis to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

August 22, 2024 | DTI (Ad)

Air Force quietly working with sub $10 stock on new tech

August 19 at 2:38 AM | finance.yahoo.com

ZTS Sep 2024 155.000 call (ZTS240920C00155000)

August 19 at 2:38 AM | finance.yahoo.com

ZTS Sep 2024 105.000 put (ZTS240920P00105000)

August 18, 2024 | ca.finance.yahoo.com

ZTS Sep 2024 200.000 put

August 17, 2024 | ca.finance.yahoo.com

ZTS Sep 2024 195.000 call

August 17, 2024 | ca.finance.yahoo.com

ZTS Sep 2024 165.000 put

August 22, 2024 | DTI (Ad)

Air Force quietly working with sub $10 stock on new tech

August 17, 2024 | americanbankingnews.com

Zoetis Inc. (NYSE:ZTS) Receives Average Rating of "Buy" from Analysts

August 16, 2024 | americanbankingnews.com

Zoetis (NYSE:ZTS) PT Raised to $210.00

August 14, 2024 | seekingalpha.com

Zoetis: Librela Sales Should Peak 200-300% Above Management's $1B Target

August 13, 2024 | finance.yahoo.com

Zoetis (NYSE:ZTS) jumps 5.1% this week, though earnings growth is still tracking behind five-year shareholder returns

August 13, 2024 | americanbankingnews.com

Zoetis (NYSE:ZTS) Price Target Raised to $225.00 at BTIG Research

August 9, 2024 | markets.businessinsider.com

Argus Research Remains a Buy on Zoetis (ZTS)

August 9, 2024 | markets.businessinsider.com

Morgan Stanley Sticks to Their Buy Rating for Zoetis (ZTS)

August 8, 2024 | markets.businessinsider.com

Buy Rating Reaffirmed for Zoetis Amidst Strong Financial Performance and Market Expansion

August 7, 2024 | seekingalpha.com

Zoetis Q2 Earnings: Harvesting From DTC (Rating Upgrade)

See More Headlines

Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 6/4 Dividend: 4/18/2024
Dividend Payable: 6/04/2024
Ex-Dividend for 9/4 Dividend: 7/18/2024
Last Earnings: 8/06/2024
Today: 8/21/2024
Dividend Payable: 9/04/2024
Next Earnings (Estimated): 11/07/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NYSE:ZTS
CUSIP: 98978V10
CIK: 1555280
Web: www.zoetis.com
Phone: (973) 822-7000
Fax: 302-655-5049
Employees: 14,100
Year Founded: 2012

Price Target and Rating

Average Stock Price Target: $217.11
High Stock Price Target: $237.00
Low Stock Price Target: $196.00
Potential Upside/Downside: +18.8%
Consensus Rating: Buy
Rating Score (0-4): 3.11
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): $5.19
Trailing P/E Ratio: 35.22
Forward P/E Ratio: 31.30
P/E Growth: 2.81
Net Income: $2.34 billion
Net Margins: 26.29%
Pretax Margin: 32.46%
Return on Equity: 50.67%
Return on Assets: 17.88%

Debt

Debt-to-Equity Ratio: 1.32
Current Ratio: 3.45
Quick Ratio: 2.09

Sales & Book Value

Annual Sales: $8.92 billion
Price / Sales: 9.36
Cash Flow: $6.39 per share
Price / Cash Flow: 28.61
Book Value: $10.87 per share
Price / Book: 16.82

Miscellaneous

Outstanding Shares: 456,295,000
Free Float: 455,565,000
Market Cap: $83.42 billion
Optionable: Optionable
Beta: 0.86

Social Links

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Ms. Kristin C. Peck (Age 53)
CEO & Director
Comp: $3.54M
Mr. Wetteny N. Joseph (Age 52)
Executive VP & CFO
Comp: $1.6M
Ms. Wafaa Mamilli (Age 57)
EVP, Chief Digital & Tech. Officer, Group President for China, Brazil and Preci. Animal Health
Comp: $1.36M
Ms. Heidi C. Chen (Age 57)
Employee Advisor
Comp: $1.24M
Dr. Robert J. Polzer Ph.D. (Age 55)
Executive VP and President of Research & Development
Comp: $1.18M
Ms. Roxanne Lagano (Age 59)
EVP, Chief HR Officer & Global Operations, Interim General Counsel and Corporate Secretary
Mr. Steven Frank
Vice President of Investor Relations
Mr. William Price
VP & Chief Communications Officer
Ms. Jeannette Ferran Astorga (Age 49)
Executive VP of Corporate Affairs & Communications and Chief Sustainability Officer
Mr. Nick Ashton (Age 51)
Executive VP and President of Global Manufacturing & Supply

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy Zoetis Stock? ZTS Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Zoetis Inc.:

Zoetis Inc. reported a strong quarterly earnings performance, beating the consensus estimate by $0.07 with an EPS of $1.56. This indicates the company's financial health and potential for growth.
The company has a solid return on equity of 50.67%, showcasing efficient utilization of shareholder funds to generate profits.
Zoetis Inc. has a robust net margin of 26.29%, indicating its ability to convert revenue into profit effectively.
The stock price of Zoetis Inc. is currently at $183.60, showing stability and potential for capital appreciation.
With a market cap of $83.87 billion, Zoetis Inc. is a significant player in the industry, providing investors with exposure to a large and established company.

Cons

Investors should be bearish about investing in Zoetis Inc. for these reasons:

Zoetis Inc. stock has experienced a 0.8% decrease, indicating short-term volatility that may pose risks to investors.
The company's P/E ratio of 35.42 suggests the stock may be relatively expensive compared to its earnings, potentially limiting immediate returns for investors.
With a debt-to-equity ratio of 1.32, Zoetis Inc. has a significant level of debt that could impact its financial flexibility and increase risk for investors.
The P/E/G ratio of 2.84 indicates that the stock may be overvalued relative to its expected earnings growth, potentially leading to a correction in the stock price.
Zoetis Inc. has a beta of 0.86, implying lower volatility compared to the market, which may limit potential returns for investors seeking higher-risk investments.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, August 20, 2024. Please send any questions or comments about these Zoetis pros and cons to contact@marketbeat.com.

ZTS Stock Analysis - Frequently Asked Questions

How have ZTS shares performed this year?: Zoetis' stock was trading at $197.37 at the start of the year. Since then, ZTS shares have decreased by 7.4% and is now trading at $182.81.
View the best growth stocks for 2024 here.
How were Zoetis' earnings last quarter?: Zoetis Inc. (NYSE:ZTS) announced its quarterly earnings data on Tuesday, August, 6th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis's revenue for the quarter was up 8.3% on a year-over-year basis.
Read the conference call transcript.
What is Kristin Peck's approval rating as Zoetis' CEO?: 50 employees have rated Zoetis Chief Executive Officer Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among the company's employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.
Does Zoetis have any subsidiaries?: Zoetis subsidiaries include Jorox Pty, Virtual Recall, Fish Vet Group, Performance Livestock Analytics, Ethos Diagnostic Science, ZNLabs, Phoenix Lab, and more.
Who are Zoetis' major shareholders?: Zoetis' top institutional shareholders include Bank of New York Mellon Corp (1.03%), Unisphere Establishment (0.98%), Legal & General Group Plc (0.92%) and Banque Pictet & Cie SA (0.54%). Insiders that own company stock include Kristin C Peck, Heidi C Chen, Roxanne Lagano, Willie M Reed, Robert J Polzer, Glenn David, Roman Trawicki and Gregory Norden.
View institutional ownership trends.
How do I buy shares of Zoetis?: Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
What other stocks do shareholders of Zoetis own?: Based on aggregate information from My MarketBeat watchlists, some other companies that Zoetis investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW) and Athabasca Oil (ATH).

This page (NYSE:ZTS) was last updated on 8/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Zoetis (ZTS) Stock Price, News & Analysis

Zoetis MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Dividend Coverage

Dividend Sustainability

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Insider Buying vs. Insider Selling

Percentage Held by Insiders

Percentage Held by Institutions

Earnings and Valuation

Earnings Growth

Price to Earnings Ratio vs. the Market

Price to Earnings Ratio vs. Sector

Price to Earnings Growth Ratio

Price to Book Value per Share Ratio

About Zoetis Stock (NYSE:ZTS)

ZTS Stock Price History

ZTS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

Should I Buy Zoetis Stock? ZTS Pros and Cons Explained

Pros

Cons

ZTS Stock Analysis - Frequently Asked Questions

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Overall MarketRank^™